View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
April 28, 2020

CytoDyn says leronlimab yielded positive data in Covid-19 patients

Humanised monoclonal antibody drug leronlimab has shown ‘impressive results’ in a small observational Covid-19 study, said the drug’s developer CytoDyn CEO Dr Nader Pourhassan in a conference call.

Originally developed to treat HIV, the drug is a CCR5 antagonist that inhibits viral entry. It is undergoing Phase II clinical trials as a treatment for HIV and secured fast-track designation from the US Food and Drug Administration (FDA).

The drug’s ability to mitigate cytokine storm is the basis for its study as a potential Covid-19 treatment.

Read the full article here

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena